A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?» Read More
Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.
Officials have yet to keep their promise to disclose how many people are signing up during a special Obamacare enrollment season.
The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.
How many of you who have Obamacare went to the doctor's office more often?
For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.
The world is facing a serious water crisis. Former NFL star Jack Brewer highlights a couple of companies investing in solutions.
A bipartisan compromise to overhaul Medicare bucks the popular impression that Washington can't accomplish anything at all.
Investors are bailing on biotech stocks at such a rapid pace that it is shocking even some of the most-seasoned traders.
Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.
Employers have ratcheted up the financial incentives they offer workers to participate in wellness programs to a record this year.
Lower-income earners were much more likely to sign up for HealthCare.gov plans, higher earners were cooler to the Obamacare marketplace.
Susquehanna's Stacey Gilbert thinks biotech could be due for a pullback. She lays out an options strategy to protect your biotech holdings.
Half of the households that received Obamacare subsidies will have to pay some of that money back, with an average repayment of nearly $800.
Angelina Jolie says she has had her ovaries and fallopian tubes removed to prevent cancer.
Hospitals have seen reductions in the costs of caring for the uninsured, but nowhere more so than in states that expanded Medicaid.
CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.
Anecdotal data suggests that many citizens appear to be opting to pay a fine rather than sign up for coverage under Obamacare, a report said.
Tenet and United Surgical Partners will combine their surgery centers in a deal that will give Tenet the option to buy USPI over the next five years.
Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.
Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.
Get the best of CNBC in your inbox